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Abstract
Background: Frequent failure and severe side effects of current sarcoma therapy warrants new therapeutic
approaches. The small-molecule MDM2 antagonist Nutlin-3a activates the p53 pathway and efficiently induces
apoptosis in tumours with amplified MDM2 gene and overexpression of MDM2 protein. However, the majority of
human sarcomas have normal level of MDM2 and the therapeutic potential of MDM2 antagonists in this group is
still unclear. We have investigated if Nutlin-3a could be employed to augment the response to traditional therapy
and/or reduce the genotoxic burden of chemotherapy.
Methods: A panel of sarcoma cell lines with different TP53 and MDM2 status were treated with Nutlin-3a
combined with Doxorubicin, Methotrexate or Cisplatin, and their combination index determined.
Results: Clear synergism was observed when Doxorubicin and Nutlin-3a were combined in cell lines with wild-
type TP53 and amplified MDM2, or with Methotrexate in both MDM2 normal and amplified sarcoma cell lines,
allowing for up to tenfold reduction of cytotoxic drug dose. Interestingly, Nutlin-3a seemed to potentiate the effect
of classical drugs as Doxorubicin and Cisplatin in cell lines with mutated TP53, but inhibited the effect of
Methotrexate.
Conclusion: The use of Nutlin in combination with classical sarcoma chemotherapy shows promising preclinical
potential, but since clear biomarkers are still lacking, clinical trials should be followed up with detailed tumour
profiling.
Background
The TP53 gene, coding for the transcription factor p53, is
thought to be the most frequently mutated gene in can-
cer, inactivated in about 50% of all tumours. However,
aberrations of this pathway are probably even more wide-
spread, as tumours retaining wild-type p53 (TP53
Wt)
might have defects in other parts of the pathway [1]. In
sarcomas, malignant tumours resembling mesenchymal
tissue, amplification of MDM2 (murine double minute 2)
is relatively common (20%) in tumours having TP53
Wt,
resulting in disabled p53 function because overexpressed
MDM2 protein binds to and inactivates p53 [2,3].
Remaining tumours may have other aberrations in their
p53 pathway, either p53 mutations (TP53
Mut,1 1 - 3 1 %
depending on subtype), or other changes in the down-
stream pathway that do not affect the level of MDM2
(MDM2
Wt/TP53
Wt, 11-88% depending on subtype) [4-6].
Sarcomas are among the more frequent cancers
among children [7], and both children and adults are
treated with intensive surgery, chemotherapy or radia-
tion, or a combination of these. Currently used
chemotherapy (e.g. Methotrexate, Cisplatin and Doxoru-
bicin) is frequently inadequate, with 50-80% long-term
survival depending on tumour subgroup [8,9] and asso-
ciated with severe toxicity. Due to the frequent failure
of prevailing therapy and unacceptable adverse effects
there is an urgent need for new therapeutic modalities
in sarcoma.
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MDM2 interaction, has been shown to be highly effec-
tive in killing osteosarcoma cells in vitro and reducing
tumour burden in vivo [10,11]. Nutlin-3a displaces p53
from the binding pocket of MDM2 and thereby releases
p53 from inhibition and proteasomal degradation, lead-
ing to induction of its downstream targets, cell cycle
arrest, and apoptosis. Tumours with amplification of the
MDM2 gene (MDM2
Ampl) are most responsive to
Nutlin, most likely due to otherwise intact downstream
p53 signalling [11]. However, the apoptotic response in
cancer cells with normal levels of MDM2 can vary dra-
matically, suggesting that other mechanisms or modify-
ing factors are involved in the response to MDM2
antagonists. Several studies have suggested both p53-
related and unrelated factors, such as caspases, BAX,
PUMA, p73 and other apoptotic factors to be involved
[10,12-14], and the status of the related MDM4 (also
known as MDMX) gene has also been proposed to
explain the responses to Nutlin [15-17].
Early studies suggest that MDM2 antagonists may be
particularly effective in sarcomas because MDM2 is
frequently amplified in these tumours [2,5,18,19]. We
previously confirmed the effectiveness of Nutlin-3a as
as i n g l ea g e n ti nTP53
Wt/MDM2
Ampl liposarcomas
[20]. However, since many sarcomas are TP53
Wt but
do not have amplified MDM2 (are MDM2
Wt), it would
be of interest to investigate if Nutlin-3a could potenti-
ate the response of MDM2
Wt/TP53
Wt tumours to con-
ventional chemotherapy. Since p53 mutations are very
heterogeneous, different mutations sites could also
imply different response to combined therapy. Nutlin
has been shown to be synergistic with genotoxic drugs
(e.g. Fludarabine, Chlorambucil, Doxorubicin, Etopo-
side, Melphalan and Cisplatin) in haematological
malignancies, lymphoma, neuroblastoma and hepato-
cellular carcinoma, and with radiation in lung cancer
[12,21-26], but antagonistic with antimitotic agents
(e.g. Paclitaxel) in colon cancer cell lines [27]. Pacli-
taxel was shown to be synergistic in rhabdomyosar-
coma cell lines [28]. Here, we investigate the effect of
Nutlin-3a on sarcoma cell lines in combination with
the current standard of therapy (e.g. Doxorubicin,
Cisplatin and Methotrexate). These are well known
and frequently used genotoxic drugs that induce cell
cycle arrest and apoptosis through both p53-dependent
and-independent mechanisms [29-31]. The latter group
is represented by Methotrexate, which primarily inhi-
bits dihydrofolate reductase (DHFR), but also glycina-
mide ribonucleotide formyltransferase (GARFT) and
thymidylate synthetase (TS), all key components of
nucleotide biosynthesis. Our studies show significant
potentiation and/or reduction of effective dose of cyto-
toxic drugs by Nutlin, in both wild-type and mutated
TP53 tumours, suggesting that clinical combination
studies in sarcoma are warranted.
Methods
Cell lines and culture conditions
We selected 5 different sarcoma cell lines, three with
TP53
Wt and two with TP53
Mut.T w oc e l ll i n e sh a d
MDM2
Ampl and three had MDM2
Wt(Table 1). The cell
line T778 (94778), kindly provided by Dr Florence Ped-
eutour, was established from a relapsed liposarcoma at
Hopital de l’Arche [32]. Dr. A Thomas Look at St Jude’s
hospital, Memphis, USA, kindly donated the cell lines
RMS13 [33] and OSA (available from the ATCC, Rock-
ville, MD as SJSA-1 or CRL2098). SaOS-2 (HTB85) and
U2OS (HTB96) were purchased from the ATCC. All
cell lines were grown in RPMI 1640 medium (Bio Whit-
taker, Verviers Belgium) containing 20 mM HEPES and
2 mM GlutaMax (GIBCO BRL Life Technologies, Pais-
ley UK), 50 IE/ml penicillin, 0,1 μg/ml streptomycin
(Bio Whittaker, Verviers Belgium) and 8% heat-inacti-
vated fetal bovine serum (PAA Laboratories, Pasching,
Austria) in an environment containing 5% CO2 at 37°C.
Direct sequencing mutation analysis of TP53
Genomic DNA was extracted from cell lines using the
standard phenol chloroform method. The total protein
coding region of TP53 (exon 2 to 11) was amplified in
five distinct fragments by using flanking intronic pri-
mers with M13 tails [34], generating products of 837,
464, 887, 300 and 275 base pairs respectively. In short,
Table 1 Cell line characteristics
Cell line Histology Patient sex/age Origin Site TP53 status MDM2 copy number MDM2 mRNA level
T778 DDLS F/69 Relapse Retroperitoneum wt 59.8 ± 1.8 28.5 ± 1.6
OSA (SJSA-1) OS M/19 Primary Femur wt 49.1 ± 1.1 43.2 ± 9.4
U2OS OS F/15 Primary Tibia wt 0.7 ± 0.1 3.1 ± 0.2
RMS13 RMS M/17 Primary Bone marrow mut
(exon 8)
1.9 ± 0.2 0.9 ± 0
SaOS-2 OS F/11 Unknown Unknown del 1.4 ± 0.2 2.5 ± 0.2
Panel of cell lines tested. DDLS refers to de-differentiated liposarcoma, OS osteosarcoma and RMS rhabdomyosarcoma. RMS13 was initially classified TP53
Wt,b u t
reclassified as TP53
Mut after extended DNA sequence analysis. MDM2 copy number and expression were determined previously as described in Müller et al, 2007.
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reactions using identical conditions for each primer pair.
We used HotStar Polymerase (Qiagen, GmbH, Ger-
many) for PCR. The quality and quantity of the resulting
PCR product was evaluated on a polyacrylamide gel, and
the product was purified using ExoSAP-IT (USB Cor-
poration, Cleveland, Ohio, USA). Both 5’ and 3’ sequen-
cing reactions were performed using BigDye terminator
v 3 . 1k i tf r o mA p p l i e dB i o s y s t ems (Foster City, Califor-
nia, USA) and adding M13 primers to the PCR product.
The resulting sequence product was further purified
using Millipore multiscreen plates (Millipore, Billerica,
Massachusetts, USA) with Sephadex G-50 Superfine (GE
Healthcare, Chalfont St. Giles, United Kingdom), and
subjected to sequencing on a 3730 DNA Analyzer
(Applied Biosystems). Where a mutation was detected, a
new independent PCR product was subjected to sequen-
cing to confirm our findings.
Drug sensitivity assay
Cellular integrity was measured as total cellular protein
by the Sulforhodamine B (SRB) assay, which was per-
formed essentially as described previously [35]. Briefly,
in a 96-well plate (Becton Dickinson), cells were seeded
in 100 μl/well at appropriate cell densities; 500 cells per
well for OSA, 1 500 for T778, 10 000 for RMS13, 2 000
for U2OS and 8 000 for SaOS-2. At these densities the
untreated control cells were growing exponentially dur-
ing the entire incubation period. After 24 hours, 100 μl
drug-containing medium was added and the cells were
cultured for another 120 hours.
All cell lines were exposed to the drugs alone or in
combination. The IC50 of the individual drug was deter-
mined where after combinations were made based on
t h er a t i oo ft h eI C 5 0 ’s. Drugs were added in a constant
ratio design. For Doxorubicin and Cisplatin three fixed
ratios were set: Ratio 1:1 = IC50Nutlin-3a: IC50x, ratio 1:2
=I C 5 0 Nutlin-3a: 2 times IC50x and ratio 2:1 = 2 times
IC50Nutlin-3a: IC50x , where x is the chemotherapy. For
Methotrexate we used the 1:1 ratio only. When the ratio
was set, a mixture of the two drugs was made and seri-
ally diluted to obtain a good dosage range.
After exposure, cells were fixed with 50% Trichloroa-
cetic acid (TCA, Sigma-Aldrich, 25 μl/well), washed and
stained with 0.4% Sulforhodamine B (SRB, Sigma-
Aldrich) dissolved in 1% acetic acid (Merck, 50 μl/well),
subsequently washed five times with 1% acetic acid to
remove unbound stain. Protein bound stain was dis-
solved in 150 μl 10 mM Tris base (Merck). Optical den-
sity was measured at 540 nm in a Victor Wallac 1420
multi-label counter (Perkin Elmer, MA USA). Relative
Growth was calculated as follows:

(ODtreated − ODzero)/(ODcontrol − ODzero)

× 100%
when ODtreated -O D zero > 0; Cell death occurred if
ODtreated -O D control <0 ,w h e r eO D treated represents the
optical density of treated cells at the day of the assay,
ODcontrol the optical density of the untreated control
cells and ODzero the optical density at the moment of
drug addition. From the relative growth we obtain the
fraction affected (Fa) as follows:
1 −

(ODtreated − ODzero)/(ODcontrol − ODzero)

.
Combination analysis
To evaluate the pharmacological interaction of the dif-
ferent combinations of drug treatments, we followed the
method proposed by Chou et al. [36] Briefly, synergism,
additivity or antagonism for the different combinations
was calculated on the basis of the multiple drug-effect
equation and quantitated by the combination index (CI)
where CI = 1 indicates that the two drugs have additive
effect, CI < 1 more than additive effect ("synergism”)
and CI > 1 less than additive effect ("antagonism”). The
involved drugs were assumed mutually non-exclusive
meaning that they have totally independent modes of
action and the CI was calculated using the CalcuSyn
software based on:
CI = (D)1/(Dx)1 + (D)2/(Dx)2 + (D1)(D2)/(Dx)1(Dx)2
where (Dx)1 and (Dx)2 are the doses of drug 1 and
drug 2 alone inhibiting x % whereas (D1)i st h ed o s eo f
drug 1 in combination with drug 2 and (D2) the dose of
drug 2 in combination with drug 1 that gives the experi-
mentally observed x inhibition. Since our aim was to
achieve maximal effect of the drugs tested on cancer
cells, a mean CI was calculated from data points with
fraction affected (Fa) > 0.5. (Fa) < 0.5 would imply lower
growth inhibition and a large fraction of the cell popula-
tion would still grow. Fa < 0.5 was therefore considered
not relevant. Furthermore we evaluated how much each
drug dose in a synergistic combination could be reduced
at a given effect level compared with the doses for each
drug alone, the so-called dose-reduction index (DRI):
(DRI)1 = (Dx)1/(D)1 and(DRI)2 = (Dx)2/(D)2
Notably, non-synergistic combinations could also
result in reduced drug doses (DRI > 1) as illustrated by
the example: if drug A and drug B each inhibit 50% and
if (0.5A+ 0.5B) also inhibits 50% and both drugs have
no overlapping toxicity toward the host, DRI ≥ 1m a y
still be beneficial [37].
Immunoblotting
I nt h ed r u gs e n s i t i v i t ya s s a yw ec h o s eac o n s t a n tr a t i o
design with three fixed ratios as described above. By
only including the 1:1 ratio in the western analysis, our
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of different drug concentrations on the molecular
mechanisms. Cells were treated for 24 hours with
Nutlin-3a, Doxorubicin, Cisplatin, Methotrexate or
described drug combinations. They were lysed in lysis
buffer (supplemented with phosphatase and protease
inhibitor cocktails (Sigma-Aldrich)) and sonicated. 15-
30 μg of protein lysate was separated on 4-12%
NuPage BIS-Tris gradient gels (Invitrogen, CA USA)
and transferred to 0.45 μm PVDF membranes (Milli-
pore Corp., MA USA) in blotting buffer with 20% (v/v)
methanol using wet blot equipment from BIO-RAD,
CA USA. Antibodies used (monoclonal except when
noted): anti-p53 (1:3000 Santa Cruz sc-6243), anti-
MDM2 (1:300, Chemicon MAB1434), anti-MDM4
(1:20000 Bethyl Labs), anti-PUMA (1:5000, Abcam),
anti-b-actin (1:4000, Sigma-Aldrich), and polyclonal
anti-p21 (1:300, Santa Cruz sc-397). All HRP-conju-
gated secondary antibodies were from Dako, Denmark.
Bands were visualized using SuperSignal West Dura
ECL (# 34076, Pierce, IL USA) and Kodak X-VIS film
and software (Eastman Kodak, NY USA). Pictures were
merged and presented using Photoshop (Adobe Sys-
tems, USA).
Statistics
The Statistical package SPSS 13.0 was used. 2-tailed
unpaired Student’s T-test on transformed results was
used for statistical analysis. Changes were considered to
be significant when P < 0.05.
Results
We investigated the effect of combining Nutlin-3a with
the current standard of sarcoma therapy (Doxorubicin,
Cisplatin, Methotrexate) on the growth of five sarcoma
cell lines. The characteristics and sources of the cell
lines used are described in Table 1. From our previous
results we knew that the liposarcoma cell line T778 was
sensitive to Nutlin-3a and we included the osteosarcoma
cell line OSA with similar characteristics (MDM2
Ampl/
TP53
Wt) as a control cell line. As representative of
MDM2
Wt/TP53
Wt, we chose the osteosarcoma cell line
U2OS. Finally, SaOS-2 and RMS13 were chosen as
examples of two different cell lines with mutated p53.
SaOS-2 is known to be TP53
Null[38]. RMS13, previously
described as TP53
Wt, did not respond to Nutlin-3a, and
was found to have a transversion in codon 280, exon 8,
changing the amino acid from arginine to serine in the
resulting protein. Protein analysis uncovered high levels
of probably dysfunctional p53 protein and constitutively
high p21 and PUMA (see below). This is consistent with
a report that the Rh30 cell line, established indepen-
dently from a xenograft from the same patient, also had
this mutation [39] and illustrates the usefulness of
Nutlin as a probe for p53 status. The other cell lines
with TP53
Wt were validated by sequencing.
Single drug treatment
The effect of each drug alone is presented in Table 2.
The MDM2
Ampl cell lines (OSA and T778) were sensi-
tive to Nutlin-3a and showed clear dose dependence,
whereas the MDM2
Wt/TP53
Wt U2OS was less sensitive,
with an IC50 about twice that for the MDM2
Ampl cell
lines. Consistent with previous results, we were not able
to reach 50% growth inhibition for the TP53
Mut cell
lines (SaOS-2 and RMS13) when using Nutlin-3a alone.
Cisplatin, Doxorubicin and Methotrexate also inhibited
cell growth in a concentration-dependent manner.
Figure 1 shows representative growth inhibition curves
for the MDM2
Ampl/TP53
Wt OSA and MDM2
Wt/TP53
Mut
RMS13 exposed to single drugs. In all cell lines tested,
Doxorubicin and Methotrexate were more cytotoxic
than Cisplatin or Nutlin-3a when used alone (Table 2),
and Methotrexate was most effective in the MDM2
Ampl
cell lines. Doxorubicin on the other hand was most
cytotoxic in the TP53
Mut line, RMS13. For Cisplatin, the
most sensitive cell line tested was OSA, followed by
RMS13, U2OS, T778 and SaOS-2.
Combination treatments
Multiple drug-effect analysis was performed for combi-
nations of Nutlin-3a with Doxorubicin, Cisplatin or
Methotrexate using the CalcuSyn software. Fraction
affected (Fa) values (indicating the fraction of cells
inhibited after drug exposure) were obtained after expo-
sure of the cells to a series of drug concentrations. To
indicate the effects at different Fa values, combination
index (CI) values were calculated for each Fa. For the
TP53
Mut cell lines RMS13 and SaOS-2 we were not able
to calculate any combination effect since the cell lines
did not respond to Nutlin-3a. Figure 2 shows an Fa-CI
plot illustrating the effects of Nutlin-3a and Doxorubicin
in a 1:1 fixed drug ratio combination and demonstrates
synergism at Fa > 0.5 for T778 whereas on average the
other two cell lines display less than additive effects. As
Table 2 Growth inhibition by Nutlin-3a, Doxorubicin,
Cisplatin and Methotrexate for the sarcoma cell lines
Mean IC50 ± SE(nM)
Drugs OSA T778 U2OS RMS13 SaOS-2
Nutlin-3a 527 ± 131 658 ± 138 1024 ± 485 na na
Dox 62 ± 77 62 ± 31 40 ± 35 14 ± 4 77 ± 12
Cis 758 ± 592 1566 ± 1369 1037 ± 596 855 ± 143 4828 ± 4855
Mtx 30 ± 9 59 ± 74 181 ± 153 106 ± 34 636 ± 806
Cells were exposed to a concentration range of Nutlin-3a, Doxorubicin,
Cisplatin and Methotrexate for 120 h. Values (IC50 in nM) are means ±
standard error of the mean (SE) for 3-5 experiments. RMS13 and SaOS-2 were
insensitive to Nutlin-3a consistent with their TP53
Mut.
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centrations showing efficacy, we limited the analysis to
Fa greater than 0.5. The mean CI values of the various
combinations for Fa > 0.5 are shown in Table 3A. Over-
all we found additive or more than additive effects when
Nutlin-3a was combined with Doxorubicin for 4 out of
6 ratios tested for MDM2
Ampl cell lines, whereas Cispla-
tin in combination with Nutlin-3a showed less than
additive effect for 5 out of 6 ratios. Nutlin-3a together
with Cisplatin or Doxorubicin also showed less than
additive effects in the MDM2
Wt cell line U2OS. Metho-
trexate on the other hand showed more than additive
effect when combined with Nutlin-3a for T778 and
U2OS, MDM2
Ampl and MDM2
Wt, respectively.
As expected, synergism, corresponding to CI < 1,
always yielded a favourable dose reduction index (DRI >
1) for both drugs. The DRI values at IC75,I C 90 and IC95
are reported in Table 3B. These indicate that che-
motherapy doses may be significantly reduced for com-
binations with Nutlin-3a that are synergistic. In both
MDM2
Ampl cell lines, Doxorubicin could be reduced 10-
fold and in T778 the Cisplatin dose could also be signif-
icantly reduced when combined with Nutlin at a 2:1
ratio. In addition, in cell lines being MDM2
Ampl or
MDM2
Wt,T 7 7 8a n dU 2 O Sr e s p e c t i v e l y ,w ef o u n dt h a t
reduced dose of Methotrexate would suffice when com-
bined with Nutlin-3a. Some combinations that were not
synergistic also maintained efficacy with reduced level of
standard cytotoxic drugs (DRI > 1) when combined with
Nutlin-3a. This holds for all combinations with Doxoru-
bicin or Methotrexate as well as some with Cisplatin.
Moreover, as depicted in Table 4 Nutlin-3a clearly
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Figure 1 Representative growth inhibition curves for OSA (A) and RMS13 (B) after Nutlin-3a, Doxorubicin, Cisplatin and Methotrexate
exposures. Exponentially growing cancer cells with TP53
Wt(OSA) or TP53
Mut(RMS13) were incubated with a range of drug concentrations for 120
h. Relative growth was measured by the SRB assay.
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Page 5 of 11potentiated Doxorubicin and Cisplatin in RMS13 and
SaOS-2 whereas Methotrexate was inhibited.
Protein analysis
Since most classic cytotoxic drugs exert their antitu-
mour effect at least in part by activation of the p53
pathway, we investigated some key downstream p53 tar-
gets by Western blotting. As expected, Nutlin-3a
i n d u c e da c c u m u l a t i o no fp 5 3p r o t e i ni nt h eMDM2
Ampl
cell lines (Figure 3A-B and 3F), followed by activation
and accumulation of p53 targets p21 and MDM2.
Although the response was weaker than for Nutlin-3a
alone, Doxorubicin and Cisplatin also induced p53 and
its downstream targets as did the combinations. Similar
to Nutlin-3a, Methotrexate induced and increased p53
in these cells, but downstream targets such as p21 and
MDM2 appeared unaffected in T778. PUMA was unaf-
fected in OSA, but induced to a similar level by all
treatments in T778. The MDM2
Wt cell line U2OS
(Figure 3C and 3F) also displayed significant induction
of p53, p21, and MDM2 after Nutlin-3a treatment alone
and in combinations, whereas Cisplatin, Doxorubicin
and Methotrexate alone had less effect. In this cell line,
neither Nutlin-3a nor the classical drugs affected the
level of PUMA, but MDM4 was completely knocked
down by Methotrexate (Figure 3C and 3F), both alone
and in combination with Nutlin-3a. It should be noted
that U2OS expressed a 62 kDa variant of MDM4,
whereas all the other lines expressed the 49 kDa band
(Figure 3). In cell lines where p53 was not functional
(RMS13 and SaOS-2), the downstream targets were not
affected by any of the treatments, as expected (Figure
3D-F). Taken together we found that the combination
treatments induced the p53 pathway proteins examined
in all TP53
Wt cell lines, whereas in TP53
Mut cell lines
they were unaffected (Figure 3A-F).
Discussion
Current treatment options for sarcomas, based on dec-
ades of optimising high dose chemotherapy, surgery and
radiation, have reached a plateau with long-term survival
limited to 50-80% depending on tumour subgroup [8,9].
Although some new targeted treatments have been suc-
cessful in other cancer types and also in some sarcoma
subtypes (e.g. GIST) [40], these treatments rarely
increase long-term survival. Since sarcomas are among
the most frequent childhood cancers, the possibility of
reducing the long-term adverse effects of high-dose che-
motherapy is an important objective. Thus, new treat-
ments targeting key cancer pathways are highly
desirable. One such pathway is the p53 tumour suppres-
sor pathway.
Although TP53 mutations are not so frequent in sar-
comas [41], the pathway may also be inactivated by
amplification of the MDM2 gene [2,5,18] which is
observed almost exclusively in tumours where TP53 is
wild-type. However, these two mechanisms do not
account for all tumours, and although some comple-
mentary mechanisms have been suggested [6], it is still
unclear if and how the pathway is inactivated in the
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Figure 2 Illustrative Fa-CI plot for the combination of Nutlin-3a and Doxorubicin using a 1:1 fixed drug ratio. CI values are calculated
from each Fa for the three Nutlin-3a sensitive cell lines in the study. Here we demonstrate average synergism at Fa > 0.5 for T778 whereas OSA
and U2OS display average antagonism.
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Page 6 of 11remainder of sarcomas. If tumours contain defects of
the p53 pathway that are upstream of p53 or suppress
p53 levels, activation of p53 could bypass the defect
and, provided the right signals are present, either induce
apoptosis directly or sensitize the cells to induction of
apoptosis by traditional therapy.
Small-molecule MDM2 antagonists such as Nutlin-3a
are interesting in this aspect not only as therapeutic
agents, but as tools to study p53 pathway functionality
[11]. Nutlins efficiently activate p53 signalling and
induce cell cycle arrest and apoptosis in sensitive cancer
cells, while sparing most normal cells when tested in
Table 3 Effects of combining Nutlin-3a with chemotherapy
A
Combination Index
Drug combination with Nutlin-3a OSA T778 U2OS
CI ± SE CI ± SE CI ± SE
Dox 1:1 1,2 ± 0,3 antagonism 0,7 ± 0,2 synergy 1,1 ± 0,2 antagonism
1:2 1,0 ± 0,1 additivity 1,4 ± 0,4 antagonism 2,1 ± 0,7 antagonism
2:1 0,8 ± 0,1 synergy 0,9 ± 0,2 synergy 1,7 ± 0,6 antagonism
Cis 1:1 1,9 ± 0,6 antagonism 1,2 ± 0,2 antagonism 1,4 ± 0,3 antagonism
1:2 2,1 ± 0,6 antagonism 1,2 ± 0,4 antagonism 2,4 ± 0,6 antagonism
2:1 1,1 ± 0,3 antagonism 0,7 ± 0,2 synergy 1,4 ± 0,2 antagonism
Mtx 1:1 1,4 ± 0,4 antagonism 0,9 ± 0,4 synergy 0,9 ± 0,3 synergy
B
Dose Reduction index values (mean ± s.e.)
75% 90% 95%
Drug combination Nutlin-3a Chemotherapy Nutlin-3a Chemotherapy Nutlin-3a Chemotherapy
OSA Nutlin-3a+Dox 1:1 1.5 ± 0.4 6.8 ± 3 1.4 ± 0.4 6.8 ± 2 1.3 ± 0.4 7.2 ± 2
Nutlin-3a+Dox 1:2 2.6 ± 0.5 2.5 ± 0.6 2.5 ± 0.5 3.2 ± 0.5 2.5 ± 0.6 3.8 ± 0.7
Nutlin-3a+Dox 2:1 1.9 ± 0.3 7.6 ± 2 1.4 ± 0.1 7.8 ± 2 1.2 ± 0.0 8 ± 2
Nutlin-3a+Cis 1:1 2.0 ± 0.5 2.0 ± 0.4 1.6 ± 0.4 1.9 ± 0.5 1.4 ± 0.4 1.9 ± 0.6
Nutlin-3a+Cis 1:2 2.6 ± 0.7 1.3 ± 0.3 2.1 ± 0.5 1.2 ± 0.3 1.8 ± 0.5 1.2 ± 0.3
Nutlin-3a+Cis 2:1 3.5 ± 2 6.3 ± 2 2.4 ± 1 4.7 ± 1 1.8 ± 0.8 4.1 ± 1
Nutlin-3a+Mtx 1:1 1.0 ± 0.1 3.7 ± 0.9 0.7 ± 0.2 4.7 ± 0.6 0.7 ± 0.3 5.7 ± 1
T778 Nutlin-3a+Dox 1:1 2.2 ± 0.5 8.1 ± 2 2.1 ± 0.6 14.1 ± 6 2.1 ± 0.7 21.1 ± 9
Nutlin-3a+Dox 1:2 1.7 ± 0.4 3.4 ± 1 1.2 ± 0.3 3.7 ± 1 1.0 ± 0.2 4.0 ± 1
Nutlin-3a+Dox 2:1 1.2 ± 0.2 9.2 ± 3 0.8 ± 0.2 9.3 ± 3 0.6 ± 0.2 9.5 ± 3
Nutlin-3a+Cis 1:1 2.1 ± 0.2 2.3 ± 0.4 1.8 ± 0.2 2.9 ± 0.9 1.6 ± 0.2 3.7 ± 2
Nutlin-3a+Cis 1:2 3.7 ± 1.2 2.0 ± 0.6 3.4 ± 1 2.9 ± 2 3.3 ± 1 4.1 ± 3
Nutlin-3a+Cis 2:1 3.2 ± 1 6.8 ± 2 2.8 ± 1 9.9 ± 6 2.5 ± 1 13.5 ± 9
Nutlin-3a+Mtx 1:1 5.2 ± 2 3.1 ± 1 3.9 ± 2 2.3 ± 0.9 3.5 ± 2 1.8 ± 0.8
U2OS Nutlin-3a+Dox 1:1 1.2 ± 0.2 9.5 ± 4 1.1 ± 0.4 6.0 ± 2 1.2 ± 0.5 4.8 ± 2
Nutlin-3a+Dox 1:2 1.2 ± 0.4 4.2 ± 2 1.3 ± 0.4 4.2 ± 2 1.3 ± 0.4 4.2 ± 2
Nutlin-3a+Dox 2:1 1.1 ± 0.4 13.1 ± 5 1.1 ± 0.5 10.6 ± 4 1.2 ± 0.5 9.3 ± 3
Nutlin-3a+Cis 1:1 1.8 ± 0.5 3.0 ± 0.7 1.9 ± 1 2.6 ± 1 2.1 ± 1 2.8 ± 2
Nutlin-3a+Cis 1:2 1.6 ± 0.4 1.4 ± 0.4 1.4 ± 0.6 1.0 ± 0.3 1.4 ± 0.7 0.9 ± 0.4
Nutlin-3a+Cis 2:1 1.4 ± 0.2 6.1 ± 3 1.1 ± 0.2 4.1 ± 0.8 0.9 ± 0.2 3.5 ± 0.7
Nutlin-3a+Mtx 1:1 1.5 ± 0.4 6.9 ± 2 1.3 ± 0.4 6.2 ± 2 1.1 ± 0.4 5.8 ± 2
A Combination Index (CI) values listed in the table are means ± standard error of the mean (SE) for Fa-values > 0.5, indicating additivity, more than additivity
(synergy) or less than additivity (antagonism). Values were determined experimentally and calculated using the Chou and Talalay method and CalcuSyn software.
Relative growth was assessed 120 h after drug treatment. Data is shown as combinations of Nutlin-3a with Doxorubicin, Cisplatin or Methotrexate in 1:1, 1:2 and
2:1 ratios. Since Nutlin-3a is not active in RMS13 and SaOS-2 it was by definition not possible to calculate their CI. B Dose Reduction Index (DRI) values for the
three combinations at 75, 90 and 95% levels of growth inhibition of OSA, T778 and U2OS cell growth.
CI < 1: more than additivity (synergy).
CI = 1: additivity.
CI > 1: less than additivity (antagonism).
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Page 7 of 11vitro [10-13,15,23,27,42]. However, their safety in
humans is still unknown, especially when combined
with traditional cytotoxic therapy. Although it has been
shown that Nutlin alone is very efficacious in
MDM2
Ampl sarcoma cell lines in vitro and in vivo
[11,20], the effects of combinations with standard thera-
peutics in sarcomas is still unknown. The aim of this
study was to investigate possible synergistic interactions
between traditional sarcoma drugs and Nutlin-3a.
As expected, cell lines with wild-type TP53 responded
to Nutlin-3a exposure by activation of p53 and its
downstream targets, including p21 and MDM2, whereas
tumours with mutated TP53, irrespective of mutation
site, did not respond to Nutlin-3a alone. MDM2
Ampl cell
lines were more sensitive to Nutlin-3a compared to the
MDM2
Wt cell lines in spite of similar levels of induction
of p21, MDM2 and PUMA. This is probably the result
of other yet undiscovered defects in the downstream
p53 signalling in the MDM2
Wt cells. MDM4 is an
MDM2 homologue that shares some of the same p53
binding sites as MDM2, although there are some differ-
ences [43]. It has been suggested that high levels of
MDM4 may counteract Nutlin because its binding to
p53 is not inhibited by the treatment [15,16,44],
although the hypothesis is still controversial [45].
The genotoxic agents tested in this study are com-
monly used in sarcoma treatment. Doxorubicin and
Methotrexate were quite effective in these cell lines,
whereas higher doses of Cisplatin and Nutlin-3a were
required in the TP53
Wt lines. Neither Doxorubicin nor
Cisplatin showed consistent differences in effect in rela-
tion to MDM2 amplification or TP53 mutation, but the
TP53 mutated cell line (RMS13) was more sensitive to
all three genotoxic agents tested than the TP53 null cell
line (SaOS-2). Methotrexate was more effective in the
lines with MDM2 amplification, suggesting some rela-
tion between MDM2 and the Methotrexate mechanism
of action that warrants further investigation.
The DRI values clearly illustrated the benefit of the
synergistic combinations, with 10-fold reductions in Dox-
orubicin and Cisplatin when combined with Nutlin-3a,
but also combinations with less than additive effects
showed promising DRI values. Nutlin-3a and Doxorubicin
or Cisplatin were less than additive in the MDM2
Wt/
TP53
Wt U2OS cell line. This is consistent with previous
results in colon (HCT116) and ovarian (A2780) cancer
cells, where Nutlin was cytoprotective in combination
with Cisplatin [14]. Compellingly the TP53
Mut cell lines,
RMS13 and SaOS-2, showed a significant sensitization
towards Cisplatin and Doxorubicin at IC50 when com-
bined with Nutlin-3a. This apparently p53-independent
effect of Nutlin-3a is in line with previous publications
[46-48], and suggests efficacy against a wide spectrum of
tumours. p73 has been proposed to be one of the factors
responsible for the effect observed in TP53-null or-mutant
cells. It was reported that when cells with dysfunctional
TP53 were exposed to high concentrations of Nutlin (e.g.
20-30 μM), p73 was displaced from its binding to MDM2,
resulting in cell cycle arrest and apoptosis [25,46,49].
Nutlin combined with Cisplatin or Doxorubicin has also
previously been reported to induce apoptosis much more
efficiently than either drug alone in cells with dysfunc-
tional TP53, most likely due to E2F1-mediated up-regula-
tion of p73 activity [48].
The third chemotherapy tested here, Methotrexate,
acts through nucleotide metabolism, for which E2F1 is a
central transcription factor [50,51]. Additional targeting
of the p53 pathway by Nutlin-3a could be complemen-
tary to this mode of action [52]. We found synergistic
effects for both TP53
Wt/MDM2
Ampl and TP53
Wt/
MDM2
Wt cell lines and DRI values that implied that
Methotrexate could be reduced ten-fold when combined
with Nutlin-3a. In the MDM2
Wt cell line U2OS, treat-
ment with Methotrexate decreased MDM4 to undetect-
able levels both alone and in combination with Nutlin-
3a. According to the current hypothesis, reduction of
MDM4 could lead to more unbound p53 [53], but since
this reduction also happened with Methotrexate only, it
would not contribute to the observed synergy. On the
other hand, Nutlin-3a can indirectly reduce the level of
E2F1 through MDM2 mediated degradation [48], and
recent results also document the reduction of DHFR
through MDM2 [54]. It is tempting therefore to specu-
late on a double inhibition of the nucleotide metabolism
when using Methotrexate together with Nutlin-3a. The
inhibitory effect observed in the TP53
Mut cell line
Table 4 Growth inhibition of combination treatment in TP53
Mut cell lines
Mean IC50 ± SE(nM)
Doxorubicin Cisplatin Methotrexate
alone combination alone combination alone combination
RMS13 14 ± 4 6 ± 3 855 ± 143 244 ± 85 106 ± 34 253 ± 75
SaOS-2 77 ± 12 40 ± 17 4828 ± 4855 517 ± 229 636 ± 806 na
RMS13 and SaOS-2 cells were exposed to a concentration range of Nutlin-3a, Doxorubicin, Cisplatin, Methotrexate and combinations for 120 h. Values (IC50 in
nM) are means ± standard error of the mean (SE) for 3-5 experiments. The decrease observed in the combination of Nutlin-3a with Doxorubicin or Cisplatin,
indicates that Nutlin-3a potentiates Doxorubicin and Cisplatin, whereas the increase in IC50 observed for the combination with Methotrexate indicates that
Nutlin-3a inhibits Methotrexate.
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Figure 3 Nutlin-3a modulates MDM2-binding proteins in a p53-dependent manner. Cell lines were exposed to drug-free media (Ctrl),
Nutlin-3a (N), Cisplatin (Cis), Doxorubicin (Dox), Methotrexate (Mtx), Nutlin-3a combined with Cisplatin (N:C), Doxorubicin (N:D) or Methotrexate
(N:M) in 1:1 ratios. A and B illustrate the induction of p53 pathway components by N:C and N:D combinations in the two MDM2
Ampl cell lines
OSA and T778. C U2OS (MDM2
Wt) displays specific reduction in MDM4 (62kDa) after Methotrexate exposure alone or in combination with Nutlin-
3a. D and E display the TP53
Mut cell lines RMS13 and SaOS-2 respectively. The figure shows representative western blots of 3 independent
biological experiments, targeting p53, p21, MDM2, MDM4, PUMA, and b-actin (loading control). Figure F illustrates quantitative measurements of
the same three western blot experiments, values representing mean fold induction ranging from 0.8 (green) to 2.6 fold (red).
Ohnstad et al. BMC Cancer 2011, 11:211
http://www.biomedcentral.com/1471-2407/11/211
Page 9 of 11(RMS13), could not be explained by this and clearly
needs further investigation.
Conclusions
Our in vitro data suggest that MDM2 antagonists could
offer effective therapy for sarcoma either as single agent
or in combination with prevailing chemotherapy, and
m a ys i g n i f i c a n t l yr e d u c et h eg e n o t o x i cb u r d e nw i t ht h e
same or better antitumour effect. Further work with ani-
mal models of sarcoma and ultimately clinical studies
needs to be done to evaluate and optimize combinations
of Nutlin and current chemotherapies. Since clear bio-
markers are still lacking, clinical trials should be fol-
lowed up with detailed tumour profiling.
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